Yuhan Corporation, First Traditional Pharmaceutical Company to Surpass 2 Trillion KRW in Sales Last Year

Operating Profit Slows to 47.6 Billion Won
Down 16% Compared to Previous Year

Exterior view of Yuhan Corporation Central Research Institute. Photo by Yuhan Corporation

Yuhan Corporation has become the first traditional pharmaceutical company to surpass 2 trillion won in sales last year.

According to Yuhan Corporation's disclosure on the 12th, the company's consolidated sales last year increased by 11.2% compared to the previous year (1.8589 trillion won), reaching 2.0677 trillion won. Operating profit was 47.6 billion won, down 16.2%.

The increase in Yuhan Corporation's sales was driven by the growth in sales of the domestic 31st new drug, the non-small cell lung cancer treatment 'Reclaza', as well as milestones and other factors.

However, the fourth quarter performance was somewhat sluggish. Fourth quarter sales amounted to 496.1 billion won, with an operating loss of 19 billion won. In the fourth quarter alone, 73.9 billion won was spent on research and development costs, which is an increase of 30.8 billion won compared to the same period last year. This is considered a temporary deficit due to increased research and development expenses.